SANDRA GOFINET PASOTO

(Fonte: Lattes)
Índice h a partir de 2011
23
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 16
  • article 51 Citação(ões) na Scopus
    Systemic manifestations of primary Sjogren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
    (2019) RETAMOZO, S.; ACAR-DENIZLI, N.; RASMUSSEN, A.; HORVATH, I. F.; BALDINI, C.; PRIORI, R.; SANDHYA, P.; HERNANDEZ-MOLINA, G.; ARMAGAN, B.; PRAPROTNIK, S.; KVARNSTROM, M.; GERLI, R.; SEBASTIAN, A.; SOLANS, R.; RISCHMUELLER, M.; PASOTO, S. G.; VALIM, V.; NORDMARK, G.; KRUIZE, A. A.; NAKAMURA, H.; HOFAUER, B.; GIACOMELLI, R.; TREVISANI, V. Fernandes Moca; DEVAUCHELLE-PENSEC, V.; ATZENI, F.; GHEITA, T. A.; CONSANI-FERNANDEZ, S.; SZANTO, A.; SIVILS, K.; GATTAMELATA, A.; DANDA, D.; KILIC, L.; BARTOLONI, E.; BOMBARDIERI, S.; SANCHEZ-GUERRERO, J.; WAHREN-HERLENIUS, M.; MARIETTE, X.; RAMOS-CASALS, M.; BRITO-ZERON, P.
    Objectives: To analyse the frequency and characterise the systemic presentation of primary Sjogren's syndrome (SS) out of the ESSDAI classification in a large international, multi-ethnic cohort of patients. Methods: The Big Data Sjogren Project Consortium is an international, multicentre registry based on world-wide data-sharing and cooperative merging of pre-existing clinical SS databases from leading centres in clinical research in SS from the five continents. A list of 26 organ-by-organ systemic features not currently included in the ESSDAI classification was defined according to previous studies; these features were retrospectively recorded. Results: Information about non-ESSDAI features was available in 6331 patients [5,917 female, mean age at diagnosis 52 years, mainly White (86.3%)]. A total of 1641 (26%) patients had at least one of the ESSDAI systemic features. Cardiovascular manifestations were the most frequent organ-specific group of non-ESSDAI features reported in our patients (17% of the total cohort), with Raynaud's phenomenon being reported in 15%. Patients with systemic disease due to non-ESSDAI features had a lower frequency of dry mouth (90.7% vs. 94.1%, p<0.001) and positive minor salivary gland biopsy (86.7% vs. 89%, p=0.033), a higher frequency of anti-Ro/SSA (74.7% vs. 68.7%, p<0.001), anti-La/SSB antibodies (44.5% vs. 40.4%, p=0.004), ANA (82.7% vs. 79.5%, p=0.006), low C3 levels (17.4% vs. 9.7%, p<0.001), low C4 levels (14.4% vs. 9.6%, p<0.001), and positive serum cryoglobulins (8.6% vs. 5.5%, p=0.001). Systemic activity measured by the ESSDAI, clinESSDAI and DAS was higher in patients with systemic disease out of the ESSDAI in comparison with those without these features (p<0.001 for all comparisons). Conclusions: More than a quarter of patients with primary SS may have systemic manifestations not currently included in the ESSDAI classification, with a wide variety of cardiovascular, digestive, pulmonary, neurological, ocular, ENT (ear, nose, and throat), cutaneous and urological features that increase the scope of the systemic phenotype of the disease. However, the individual frequency of each of these non-ESSDAI features was very low, except for Raynaud's phenomenon.
  • article 24 Citação(ões) na Scopus
    Influence of the age at diagnosis in the disease expression of primary Sjogren's syndrome. Analysis of 12,753 patients from the Sjogren Big Data Consortium
    (2021) RETAMOZO, S.; ACAR-DENIZLI, N.; HORVATH, I. F.; NG, W-F; RASMUSSEN, A.; DONG, X.; LI, X.; BALDINI, C.; OLSSON, P.; PRIORI, R.; SEROR, R.; GOTTENBERG, J-E; KRUIZE, A. A.; HERNANDEZ-MOLINA, G.; VISSINK, A.; SANDHYA, P.; ARMAGAN, B.; QUARTUCCIO, L.; SEBASTIAN, A.; PRAPROTNIK, S.; BARTOLONI, E.; KWOK, S-K; KVARNSTROM, M.; RISCHMUELLER, M.; SOLANS-LAQUE, R.; SENE, D.; PASOTO, S. G.; SUZUKI, Y.; ISENBERG, D. A.; VALIM, V.; NORDMARK, G.; NAKAMURA, H.; TREVISANI, V Fernandes Moca; HOFAUER, B.; SISO-ALMIRALL, A.; GIACOMELLI, R.; DEVAUCHELLE-PENSEC, V; BOMBARDIERI, M.; ATZENI, F.; HAMMENFORS, D.; MAURE, B.; CARSONS, S. E.; GHEITA, T.; SANCHEZ-BERNA, I; LOPEZ-DUPLA, M.; MOREL, J.; INANC, N.; FONSECA-AIZPURU, E.; MORCILLO, C.; VOLLENWEIDER, C.; MELCHOR, S.; VAZQUEZ, M.; DIAZ-CUIZA, E.; CONSANI-FERNANDEZ, S.; DE-MIGUEL-CAMPO, B.; SZANTO, A.; BOMBARDIERI, S.; GATTAMELATA, A.; HINRICHS, A.; SANCHEZ-GUERRERO, J.; DANDA, D.; KILIC, L.; VITA, S. de; WILAND, P.; GERLI, R.; PARK, S-H; WAHREN-HERLENIUS, M.; BOOTSMA, H.; MARIETTE, X.; RAMOS-CASALS, M.; BRITO-ZERON, P.
    Objective. To analyse how the main components of the disease phenotype (sicca symptoms, diagnostic tests, immunological markers and systemic disease) can be driven by the age at diagnosis of primary Sjogren's syndrome (pSS). Methods. By January 2021, the participant centres had included 12,753 patients from 25 countries that fulfilled the 2002/2016 classification criteria for pSS. The age at diagnosis was defined as the time when the attending physician confirmed fulfilment of the criteria. Patients were clustered according to age at diagnosis. 50 clusters with more than 100 observations (from 27 to 76 years) were used to study the influence of the age at diagnosis in the disease expression. Results. There was a consistent increase in the frequency of oral dryness according to the age at diagnosis, with a frequency of <90% in patients diagnosed at the youngest ages and >95% in those diagnosed at the oldest ages. The smooth curves that best fitted a linear model were the frequency of dry mouth (adjusted R-2 0.87) and the frequency of abnormal oral tests (adjusted R-2 0.72). Therefore, for each 1-year increase in the age at diagnosis, the frequency of dry mouth increased by 0.13%, and the frequency of abnormal oral diagnostic tests by 0.11%. There was a consistent year-by-year decrease in the frequency of all autoantibodies and immunological markers except for cryoglobulins. According to the linear models, for each 1-year increase in the age at diagnosis, the frequency of a positive result decreased by 0.57% (for anti-Ro antibodies), 0.47% (for RF) and 0.42% (for anti-La antibodies). The ESSDAI domains which showed a more consistent decrease were glandular and lymph node involvement (for each 1-year increase in the age at diagnosis, the frequency of activity decreased by 0.18%), and constitutional, cutaneous, and haematological involvements (the frequency decreased by 0.09% for each 1-year increase). In contrast, other domains showed an ascending pattern, especially pulmonary involvement (for each 1-year increase in the age at diagnosis, the frequency of activity increased by 0.22%), and peripheral nerve involvement (the frequency increased by 0.09% for each 1-year increase). Conclusion. The influence of the age at diagnosis on the key phenotypic features of pSS is strong, and should be considered critical not only for designing a personalised diagnostic approach, but also to be carefully considered when analysing the results of diagnostic tests and immunological parameters, and when internal organ involvement is suspected at diagnosis.
  • article 135 Citação(ões) na Scopus
    How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project)
    (2018) BRITO-ZERON, P.; ACAR-DENIZLI, N.; NG, W. F.; ZEHER, M.; RASMUSSEN, A.; MANDL, T.; SEROR, R.; LI, X.; BALDINI, C.; GOTTENBERG, J. -E.; DANDA, D.; QUARTUCCIO, L.; PRIORI, R.; HERNANDEZ-MOLINA, G.; ARMAGAN, B.; KRUIZE, A. A.; KWOK, S. -K.; KVARNSTROM, M.; PRAPROTNIK, S.; SENE, D.; BARTOLONI, E.; SOLANS, R.; RISCHMUELLER, M.; SUZUKI, Y.; ISENBERG, D. A.; VALIM, V.; WILAND, P.; NORDMARK, G.; FRAILE, G.; BOOTSMA, H.; NAKAMURA, T.; GIACOMELLI, R.; DEVAUCHELLE-PENSEC, V.; KNOPF, A.; BOMBARDIERI, M.; TREVISANI, V. -F; HAMMENFORS, D.; PASOTO, S. G.; RETAMOZO, S.; GHEITA, T. A.; ATZENI, F.; MOREL, J.; VOLLENVEIDER, C.; HORVATH, I-F.; SIVILS, K. L.; OLSSON, P.; VITA, S. De; SANCHEZ-GUERRERO, J.; KILIC, L.; WAHREN-HERLENIUS, M.; MARIETTE, X.; RAMOS-CASALS, M.
    Objective. To evaluate the influence of the main immunological markers on the disease phenotype at diagnosis in a large international cohort of patients with primary Sjogren's syndrome (SjS). Methods. The Big Data Sjogren Project Consortium is an international, multicentre registry created in 2014. As a first step, baseline clinical information from leading centres on clinical research in SjS of the 5 continents was collected. The centres shared a harmonised data architecture and conducted cooperative online efforts in order to refine collected data under the coordination of a big data statistical team. Inclusion criteria were the fulfillment of the 2002 classification criteria. Immunological tests were carried out using standard commercial assays. Results. By January 2018, the participant centres had included 10,500 valid patients from 22 countries. The cohort included 9,806 (93%) women and 694 (7%) men, with a mean age at diagnosis of primary SjS of 53 years, mainly White (78%) and included from European countries (71%). The frequency of positive immunological markers at diagnosis was 79.3% for ANA, 73.2% for anti-Ro, 48.6% for RF, 45.1% for anti-La, 13.4% for low C3 levels, 14.5% for low C4 levels and 7.3% for cryoglobulins. Positive autoantibodies (ANA, Ro, La) correlated with a positive result in salivary gland biopsy, while hypocomplementaemia and especially cryoglobulinaemia correlated with systemic activity (mean ESSDAI score of 17.7 for ctyoglobulins, 11.3 for low C3 and 9.2 for low C4, in comparison with 3.8 for negative markers). The immunological markers with a great number of statistically-significant associations (p<0.001) in the organ-by-organ ESSDAI evaluation were cryoglobulins (9 domains), low C3 (8 domains), anti-La (7 domains) and low C4 (6 domains). Conclusion. We confirm the strong influence of immunological markers on the phenotype of primary SjS at diagnosis in the largest multi-ethnic international cohort ever analysed, with a greater influence for cryoglobulinaemic-related markers in comparison with Ro/La autoantibodies and ANA. Immunological patterns play a central role in the phenotypic expression of the disease already at the time of diagnosis, and may guide physicians to design a specific personalised management during the follow-up of patients with primary SjS.
  • conferenceObject
    IMMUNOPATHOLOGICAL SCENARIOS DEFINING COEXISTENCE BETWEEN SJOGREN SYNDROME AND SARCOIDOSIS
    (2022) FLORES-CHAVEZ, A.; NG, F.; ALUNNO, A.; INANC, N.; ABACAR, K. Y.; FEIJOO-MASSO, C.; SEROR, R.; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; ROBLES, A.; AKASBI, M.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; RETAMOZO, S.; BANDEIRA, M.; ROMAO, V. C.; DEVAUCHELLE-PENSEC, V.; CARUBBI, F.; MARIETTE, X.; RAMOS-CASALS, M.
  • conferenceObject
    BASELINE ESSDAI/ DAS SCORES IN 8061 PATIENTS WITH PRIMARY SJOGREN SYNDROME: CHARACTERIZATION OF SYSTEMIC DISEASE
    (2017) BRITO-ZERON, P.; ACAR-DENIZLI, N.; ZEHER, M.; RASMUSSEN, A.; LI, X.; BALDINI, C.; GOTTENBERG, J-E.; DANDA, D.; QUARTUCCIO, L.; HERNANDEZ-MOLINA, G.; KRUIZE, A. A.; PARK, S-H.; KVARNSTROM, M.; PRAPROTNIK, S.; SENE, D.; ALUNNO, A.; SOLANS, R.; MANDL, T.; SUZUKI, Y.; RISCHMUELLER, M.; NORDMARK, G.; FRAILE, G.; WILAND, P.; BOOTSMA, H.; NAKAMURA, T.; VALIM, V.; GIACOMELLI, R.; SEROR, R.; DEVAUCHELLE-PENSEC, V.; HOFAUER, B.; BOMBARDIERI, M.; TREVISANI, V.; HAMMENFORS, D.; MINNITI, A.; PASOTO, S. G.; MOREL, J.; RETAMOZO, S.; GHEITA, T. A.; ATZENI, F.; VOLLENVEIDER, C.; MARIETTE, X.; RAMOS-CASALS, M.
  • conferenceObject
    SAFETY AND EFFICACY OF SARS-COV-2 VACCINATION IN 1237 PATIENTS WITH PRIMARY SJOGREN SYNDROME
    (2022) INANC, N.; KOSTOV, B.; PRIORI, R.; FLORES-CHAVEZ, A.; CARUBBI, F.; SZANTO, A.; VALIM, V.; BOOTSMA, H.; PRAPROTNIK, S.; TREVISANI, V. F. M.; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; DUPLA, M. L.; BOCCI, Bartoloni E.; RISCHMUELLER, M.; DEVAUCHELLE-PENSEC, V; ABACAR, K. Y.; GIARDINA, F.; ALUNNO, A.; HORVATH, I. F.; WOLFF, L. De; CALDAS, L.; RETAMOZO, S.; RAMOS-CASALS, M.; BRITO-ZERON, P.
  • article 16 Citação(ões) na Scopus
    Post-COVID-19 syndrome in patients with primary Sjogren's syndrome after acute SARS-CoV-2 infection
    (2021) BRITO-ZERON, P.; ACAR-DENIZLI, N.; ROMAO, V. C.; ARMAGAN, B.; SEROR, R.; CARUBBI, F.; MELCHOR, S.; PRIORI, R.; VALIM, V.; RETAMOZO, S.; PASOTO, S. G.; TREVISANI, V. Fernandes Moca; HOFAUER, B.; SZANTO, A.; INANC, N.; HERNANDEZ-MOLINA, G.; SEBASTIAN, A.; BARTOLONI, E.; DEVAUCHELLE-PENSEC, V; AKASBI, M.; GIARDINA, F.; BANDEIRA, M.; SISO-ALMIRALL, A.; RAMOS-CASALS, M.
    Objective. To analyse the frequency and characteristics of post-COVID-19 syndrome in patients with primary Sjogren's syndrome (pSS) affected by acute SARS-CoV-2 infection. Methods. By the first week of April 2021, all centres included in the Big Data Sjogren Consortium were contacted asking for patients included in the Registry diagnosed with SARS-CoV-2 infection according to the ECDC guidelines. According to the NICE definitions, symptoms related to COVID-19 were classified as acute COVID-19 (signs and symptoms for up to 4 weeks), ongoing symptomatic COVID-19 (presence of signs and symptoms from 4 to 12 weeks) and post-COVID-19 syndrome (signs and symptoms that continue for >12 weeks not explained by an alternative diagnosis after a protocolised study). Results. We identified 132 patients who were followed a mean follow-up of 137.8 days (ranging from 5 days to 388 days) after being diagnosed with COVID-19. In the last visit, 75 (57%) patients remained symptomatic: 68 (52%) remained symptomatic for more than 4 weeks fulfilling the NICE definition for ongoing symptomatic postCOVID-19, and 38 (29%) remained symptomatic for more than 12 weeks fulfilling the definition of post-COVID-19 syndrome. More than 40% of pSS patients reported the persistence of four symptoms or more, including anxiety/ depression (59%), arthralgias (56%), sleep disorder (44%), fatigue (40%), anosmia (34%) and myalgias (32%). Age-sex adjusted multivariate analysis identified raised LDH levels (OR 10.36), raised CRP levels (OR 7.33), use of hydroxychloroquine (OR 3.51) and antiviral agents (OR 3.38), hospital admission (OR 8.29), mean length of hospital admission (OR 1.1) and requirement of supplemental oxygen (OR 6.94) as factors associated with a higher risk of developing post-COVID-19 syndrome. A sensitivity analysis including hospital admission in the adjusted model confirmed raised CRP levels (OR 8.6, 95% CI 1.33-104.44) and use of hydroxychloroquine (OR 2.52, 95% CI 1.00-6.47) as the key independent factors associated with an enhanced risk of developing post-COVID-19 syndrome. Conclusion. This is the first study that analyses the frequency and characteristics of post-COVID-19 syndrome in patients affected by a systemic autoimmune disease. We found that 57% of patients with pSS affected by COVID-19 remain symptomatic after a mean follow-up of 5 months. The risk of developing post-COVID-19 syndrome in patients who required hospitalisation was 8-times higher than in non-hospitalised patients, with baseline raised CRP levels and the use of hydroxychloroquine being independent risk factors for postCOVID-19.
  • article 3 Citação(ões) na Scopus
    Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjogren syndrome
    (2022) INANC, N.; KOSTOV, B.; PRIORI, R.; FLORES-CHAVEZ, A.; CARUBBI, F.; SZANTO, A.; VALIM, V.; BOOTSMA, H.; PRAPROTNIK, S.; TREVISANI, V. Fernandes Moca; HERNANDEZ-MOLINA, G.; HOFAUER, B.; PASOTO, S. G.; LOPEZ-DUPLA, M.; BARTOLONI, E.; RISCHMUELLER, M.; DEVAUCHELLE-PENSEC, V.; ABACAR, K.; GIARDINA, F.; ALUNNO, A.; HORVATH, I. Fanny; WOLFF, L. de; CALDAS, L.; RETAMOZO, S.; RAMOS-CASALS, M.; BRITO-ZERON, P.
    Objective To investigate the safety and efficacy of SARS-Cov-2 vaccination in patients with primary Sjogren syndrome (pSS) due to scarcity of data in this population. Methods By the first week of May 2021, all Big Data SS Consortium centres patients who had received at least one dose of any SARS-CoV-2 vaccine were included in the study. The in-charge physician asked patients about local and systemic reactogenicity to collect SARS-CoV-2 vaccination data. Results The vaccination data of 1237 patients were received. A total of 835 patients (67%) reported any adverse events (AEs), including local (53%) and systemic (50%) AEs. Subjective symptoms (63%) were the most common local AEs, followed by objective signs at the injection site (16%), and general symptoms were the most commonly reported systemic AEs (46%), followed by musculoskeletal (25%), gastrointestinal (9%), cardiopulmonary (3%), and neurological (2%). In addition, 141 (11%) patients reported a significant worsening/ exacerbation of their pre-vaccination sicca symptoms and fifteen (1.2%) patients reported active involvement in the glandular (n=7), articular (n=7), cutaneous (n=6), pulmonary (n=2), and peripheral nervous system (n=1) domains due to post-vaccination SS flares. In terms of vaccination efficacy, breakthrough SARS-CoV-2 infection was confirmed after vaccination in three (0.24 %) patients, and positive anti- SARS-Cov-2 antibodies were detected in approximately 95% of vaccinated SS patients, according to data available. Conclusion Our data suggest that patients with pSS develop adequate humoral response and no severe AEs after SARS-CoV- 2 vaccination and therefore raise no concerns about the vaccine's efficacy or safety profile in this population.
  • conferenceObject
    INFLUENCE OF EPIDEMIOLOGY AND ETHNICITY ON SYSTEMIC EXPRESSION OF PRIMARY SJOGREN SYNDROME AT DIAGNOSIS: WORLDWIDE PATTERNS IN 14,836 PATIENTS (2022 SJOGREN BIG DATA PROJECT)
    (2022) RETAMOZO, S.; SZANTO, A.; LI, X.; RASMUSSEN, A.; NG, F.; DONG, X.; PRIORI, R.; OLSSON, P.; BALDINI, C.; SEROR, R.; BOOTSMA, H.; ARMAGAN, B.; GOTTENBERG, J.; KRUIZE, A.; HERNANDEZ-MOLINA, G.; PAPROVNIK, S.; DANDA, D.; OZKIZILTAS, B.; INANC, N.; QUARTUCCIO, L.; SEBASTIAN, A.; GERLI, R.; ROMAO, V. C.; RISCHMUELLER, M.; SUZUKI, Y.; KWOK, S.; KVARNSTROM, M.; SOLANS, R.; PASOTO, S. G.; GALISTEO, C.; SENE, D.; TREVISANI, V Moca; ISENBERG, D.; HOFAUER, B.; SHIMIZU, T.; NORDMARK, G.; VALIM, V.; JURCUT, C.; CARUBBI, F.; GARCIA, A. Gonzalez; DEVAUCHELLE-PENSEC, D.; DIAZ, S. Melchor; GHEITA, T. A.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; FONSECA-AIZPURU, E.; SANCHEZ-BERNA, I; MOREL, J.; GIACOMELLI, R.; ATZENI, F.; CONSANI, C.; VAZQUEZ, M.; AKASBI, M.; FLORES-CHAVEZ, A.; RAMOS-CASALS, M.
  • conferenceObject
    KEY FEATURES AT DIAGNOSIS OF PRIMARY SJOGREN SYNDROME IN 15,652 PATIENTS: 2022 SJOGREN BIG DATA PROJECT
    (2022) FLORES-CHAVEZ, A.; HORVATH, F. I.; LI, X.; RASMUSSEN, A.; NG, F.; DONG, X.; PRIORI, R.; OLSSON, P.; BALDINI, C.; SEROR, R.; BOOTSMA, H.; ARMAGAN, B.; GOTTENBERG, J.; KRUIZE, A.; HERNANDEZ-MOLINA, G.; PAPROVNIK, S.; DANDA, D.; OZKIZILTAS, B.; INANC, N.; SEBASTIAN, A.; BOCCI, Bartoloni E.; QUARTUCCIO, L.; ROMAO, V. C.; RISCHMUELLER, M.; SUZUKI, Y.; KWOK, S.; KVARNSTROM, M.; SOLANS, R.; PASOTO, S. G.; GALISTEO, C.; SENE, D.; TREVISANI, V. Moca; ISENBERG, D.; HOFAUER, B.; SHIMIZU, T.; NORDMARK, G.; VALIM, V.; JURCUT, C.; CARUBBI, F.; GARCIA, A. Gonzalez; RETAMOZO, S.; DEVAUCHELLE-PENSEC, V.; DIAZ, S. Melchor; GHEITA, T. A.; BRITO-ZERON, P.; LOPEZ-DUPLA, M.; FONSECA-AIZPURU, E.; SANCHEZ-BERNA, I.; MOREL, J.; GIACOMELLI, R.; ATZENI, F.; CONSANI, S.; VAZQUEZ, M.; AKASBI, M.